Alnylam to partner with Scangos-led biotech on infectious disease drugs

Vir Biotechnology, a San Francisco-based startup led by former Biogen CEO George Scangos, said Wednesday that it will work with Alnylam Pharmaceuticals to develop infectious disease treatments using the Cambridge company ’s experimental technology. Under the agreement, the companies will collaborate to develop one of Alnylam’s (Nasdaq: ALNY) potential drugs for hepatitis B, plus up to four additional treatments for infectious diseases. Alnylam will be eligible to receive over $1 billion in payments…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news